Skip to main content
Erschienen in: Medical Oncology 1/2015

01.01.2015 | Original Paper

Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells

verfasst von: Yue Li, Ying Wang, Suihai Wang, Yanjun Gao, Xuefeng Zhang, Chunhua Lu

Erschienen in: Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Oridonin is an active diterpenoid, which was extracted from traditional Chinese herbs and had been widely used in clinical treatment nowadays. Oridonin phosphate is one of the derivatives of oridonin. In the present study, we explored its anti-tumor effect and investigated the molecular mechanism of oridonin phosphate in breast cancer cell lines. Firstly, cell viability was analyzed by MTT assay. The breast cancer cells were treated with increasing concentrations of oridonin phosphate for 24, 48 and 72 h, respectively. The results demonstrated that oridonin phosphate inhibited the proliferation of MDA-MB-436 and MDA-MB-231 cells in a dose- and time-dependent manner. Next, cell apoptosis rate was detected in oridonin phosphate-treated breast cancer cells by Annexin V-FITC/PI dual staining analysis and the data demonstrated that oridonin phosphate induced cell apoptosis of breast cancer cells in time- and dose-dependent manner. Moreover, apoptosis-related proteins were detected by Western blotting analysis. The results showed that the expression level of Bax was up-regulated and the expression level of Bcl-2 was down-regulated. Meanwhile, the level of cleaved caspase-9 was significantly increased when the cells were treated with 40 μM of oridonin phosphate for 48 h, although the expression level of pro-caspase-9 was not obviously changed. All of the data revealed that mitochondrial apoptosis pathway may be involved in the cell apoptosis induced by oridonin phosphate in breast cancer cells. Importantly, the expression levels of autophagy-related protein beclin-1 and LC3-II were significantly higher in oridonin phosphate-treated breast cancer cell lines MDA-MB-436 and MDA-MB-231 for 48 h. Additionally, we further explored the relationship between apoptosis and autophagy specifically induced by oridonin phosphate in breast cancer cells. The result showed that inhibition of autophagy suppressed the cell apoptosis in oridonin phosphate-treated MDA-MB-436 cells. Taken together, the compound of oridonin phosphate simultaneously induced cell apoptosis and autophagy in breast cancer cells. Inhibition oridonin phosphate-induced cell autophagy suppressed the progression of cell apoptosis, which revealed that oridonin phosphate-induced autophagy participated in up-regulation of apoptosis in human breast cancer cells. It would provide some new clues for the therapy of breast cancer.
Literatur
1.
Zurück zum Zitat Battaglini CL, Mills RC, Phillips BL, et al. Twenty-five years of research on the effects of exercise training in breast cancer survivors: a systematic review of the literature. World J Clin Oncol. 2014;5:177–90.PubMedCentralPubMedCrossRef Battaglini CL, Mills RC, Phillips BL, et al. Twenty-five years of research on the effects of exercise training in breast cancer survivors: a systematic review of the literature. World J Clin Oncol. 2014;5:177–90.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Hiller D, Chu QD. CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. Int J Breast Cancer. 2011;2011:420981.PubMedCentralPubMedCrossRef Hiller D, Chu QD. CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. Int J Breast Cancer. 2011;2011:420981.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007;103:11–21.PubMedCrossRef Agrawal A, Ayantunde AA, Rampaul R, Robertson JF. Male breast cancer: a review of clinical management. Breast Cancer Res Treat. 2007;103:11–21.PubMedCrossRef
5.
6.
Zurück zum Zitat Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987–1999. Int J Cancer. 2003;106:771–83.PubMedCrossRef Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987–1999. Int J Cancer. 2003;106:771–83.PubMedCrossRef
7.
Zurück zum Zitat Yang L, Li LD, Chen YD, Parkin DM. Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi. 2006;28:438–40.PubMed Yang L, Li LD, Chen YD, Parkin DM. Time trends, estimates and projects for breast cancer incidence and mortality in China. Zhonghua Zhong Liu Za Zhi. 2006;28:438–40.PubMed
8.
Zurück zum Zitat Yu X, Deng Q, Bode AM, Dong Z, Cao Y. The role of necroptosis, an alternative form of cell death, in cancer therapy. Expert Rev Anticancer Ther. 2013;13:883–93.PubMedCrossRef Yu X, Deng Q, Bode AM, Dong Z, Cao Y. The role of necroptosis, an alternative form of cell death, in cancer therapy. Expert Rev Anticancer Ther. 2013;13:883–93.PubMedCrossRef
9.
Zurück zum Zitat Qi R, Liu XY. New advance in caspase-independent programmed cell death and its potential in cancer therapy. Int J Biomed Sci. 2006;2:211–6.PubMedCentralPubMed Qi R, Liu XY. New advance in caspase-independent programmed cell death and its potential in cancer therapy. Int J Biomed Sci. 2006;2:211–6.PubMedCentralPubMed
10.
Zurück zum Zitat Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10:13–29.PubMedCrossRef Maddika S, Ande SR, Panigrahi S, et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat. 2007;10:13–29.PubMedCrossRef
11.
Zurück zum Zitat Yoo JO, Ha KS. New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int Rev Cell Mol Biol. 2012;295:139–74.PubMedCrossRef Yoo JO, Ha KS. New insights into the mechanisms for photodynamic therapy-induced cancer cell death. Int Rev Cell Mol Biol. 2012;295:139–74.PubMedCrossRef
12.
Zurück zum Zitat Liu T, Wu LY, Choi JK, Berkman CE. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol. 2010;36:777–84.PubMedCrossRef Liu T, Wu LY, Choi JK, Berkman CE. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. Int J Oncol. 2010;36:777–84.PubMedCrossRef
13.
Zurück zum Zitat Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technol Cancer Res Treat. 2007;6:651–4.PubMedCentralPubMedCrossRef Griffin RJ, Williams BW, Bischof JC, Olin M, Johnson GL, Lee BW. Use of a fluorescently labeled poly-caspase inhibitor for in vivo detection of apoptosis related to vascular-targeting agent arsenic trioxide for cancer therapy. Technol Cancer Res Treat. 2007;6:651–4.PubMedCentralPubMedCrossRef
14.
15.
Zurück zum Zitat Du XX, Li YJ, Wu CL, et al. Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin. Biomed Pharmacother. 2013;67:417–24.PubMedCrossRef Du XX, Li YJ, Wu CL, et al. Initiation of apoptosis, cell cycle arrest and autophagy of esophageal cancer cells by dihydroartemisinin. Biomed Pharmacother. 2013;67:417–24.PubMedCrossRef
16.
Zurück zum Zitat Wang Y, Ding L, Wang X, et al. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res. 2012;4:44–51.PubMedCentralPubMed Wang Y, Ding L, Wang X, et al. Pterostilbene simultaneously induces apoptosis, cell cycle arrest and cyto-protective autophagy in breast cancer cells. Am J Transl Res. 2012;4:44–51.PubMedCentralPubMed
17.
Zurück zum Zitat Zeng Y, Li S, Wu J, et al. Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model. Apoptosis. 2014;19:1215–24. Zeng Y, Li S, Wu J, et al. Autophagy inhibitors promoted aristolochic acid I induced renal tubular epithelial cell apoptosis via mitochondrial pathway but alleviated nonapoptotic cell death in mouse acute aritolochic acid nephropathy model. Apoptosis. 2014;19:1215–24.
18.
Zurück zum Zitat Zhao X, Gao S, Ren H, Huang H, Ji W, Hao J. Inhibition of autophagy strengthens celastrol-induced apoptosis in human pancreatic cancer in vitro and in vivo models. Curr Mol Med. 2014;14:555–63.PubMedCrossRef Zhao X, Gao S, Ren H, Huang H, Ji W, Hao J. Inhibition of autophagy strengthens celastrol-induced apoptosis in human pancreatic cancer in vitro and in vivo models. Curr Mol Med. 2014;14:555–63.PubMedCrossRef
19.
Zurück zum Zitat Fujita E, Fujita T, Ito N. Studies on the constituents of the stems of Isodon trichocarpus Kudo. Yakugaku Zasshi. 1967;87:1150–3.PubMed Fujita E, Fujita T, Ito N. Studies on the constituents of the stems of Isodon trichocarpus Kudo. Yakugaku Zasshi. 1967;87:1150–3.PubMed
20.
Zurück zum Zitat Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia. 1976;32:203–6.PubMedCrossRef Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the Isodon diterpenoids: structural requirements for the activity. Experientia. 1976;32:203–6.PubMedCrossRef
21.
Zurück zum Zitat Tian W, Chen SY. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin. Chin J Integr Med. 2013;19:315–20.PubMedCrossRef Tian W, Chen SY. Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin. Chin J Integr Med. 2013;19:315–20.PubMedCrossRef
22.
Zurück zum Zitat Bao R, Shu Y, Wu X, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14:217.PubMedCentralPubMedCrossRef Bao R, Shu Y, Wu X, et al. Oridonin induces apoptosis and cell cycle arrest of gallbladder cancer cells via the mitochondrial pathway. BMC Cancer. 2014;14:217.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Sun KW, Ma YY, Guan TP, et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol. 2012;18:7166–74.PubMedCentralPubMedCrossRef Sun KW, Ma YY, Guan TP, et al. Oridonin induces apoptosis in gastric cancer through Apaf-1, cytochrome c and caspase-3 signaling pathway. World J Gastroenterol. 2012;18:7166–74.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Ye LH, Li WJ, Jiang XQ, et al. Study on the autophagy of prostate cancer PC-3 cells induced by oridonin. Anat Rec (Hoboken). 2012;295:417–22.CrossRef Ye LH, Li WJ, Jiang XQ, et al. Study on the autophagy of prostate cancer PC-3 cells induced by oridonin. Anat Rec (Hoboken). 2012;295:417–22.CrossRef
25.
Zurück zum Zitat D’Anneo A, Carlisi D, Lauricella M, et al. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. 2013;4:e891.PubMedCentralPubMedCrossRef D’Anneo A, Carlisi D, Lauricella M, et al. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. 2013;4:e891.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Huang AC, Lien JC, Lin MW, et al. Tetrandrine induces cell death in SAS human oral cancer cells through caspase activation-dependent apoptosis and LC3-I and LC3-II activation-dependent autophagy. Int J Oncol. 2013;43:485–94.PubMed Huang AC, Lien JC, Lin MW, et al. Tetrandrine induces cell death in SAS human oral cancer cells through caspase activation-dependent apoptosis and LC3-I and LC3-II activation-dependent autophagy. Int J Oncol. 2013;43:485–94.PubMed
27.
Zurück zum Zitat Nishitani H, Sugimoto N, Roukos V, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 2006;25:1126–36. Nishitani H, Sugimoto N, Roukos V, et al. Two E3 ubiquitin ligases, SCF-Skp2 and DDB1-Cul4, target human Cdt1 for proteolysis. EMBO J. 2006;25:1126–36.
28.
Zurück zum Zitat Peng R, Lin J, Wei D. Purification and characterization of an organic solvent-tolerant lipase from Pseudomonas aeruginosa CS-2. Appl Biochem Biotechnol. 2010;162:733–43. Peng R, Lin J, Wei D. Purification and characterization of an organic solvent-tolerant lipase from Pseudomonas aeruginosa CS-2. Appl Biochem Biotechnol. 2010;162:733–43.
Metadaten
Titel
Oridonin phosphate-induced autophagy effectively enhances cell apoptosis of human breast cancer cells
verfasst von
Yue Li
Ying Wang
Suihai Wang
Yanjun Gao
Xuefeng Zhang
Chunhua Lu
Publikationsdatum
01.01.2015
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 1/2015
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0365-1

Weitere Artikel der Ausgabe 1/2015

Medical Oncology 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.